More than 20 years of research on ion channels and in the field of drug discovery. Dr. Baburin served from 2014 - 2019 as CEO of ChanPharm. In addition, he developed new technologies for automated drug screening (Baburin et al. 2006) and made significant contributions to research into the cardiotoxic effects of plant extracts. In particular he discovered and characterized dehydroevodiamine and hortiamine from Evodia rutaecarpa as potent pro-arrhythmic natural products. Dr. Baburin found a new mechanism by which gamma subunits of GABA(A) receptors modulate the properties of this ligand gated ion channel (Baburin et al. 2008). From 2008–2023 he contributed as group leader to the discovery of novel natural product GABA(A) receptor modulators.